Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2021 Jun 30;225(5):584. doi: 10.1016/j.ajog.2021.06.086

Misclassification bias and unnecessary anxiety

Marian Knight 1, Elizabeth Draper 2, Jennifer J Kurinczuk 3
PMCID: PMC8278398  PMID: 34216569

To the Editors:

We read with concern the article by Gurol-Urganci et al1 purporting to show an increase in stillbirths and preeclampsia among women who received a positive test result for SARS-CoV-2 at the time of birth admission in England. This association may be explained entirely by the admission SARS-CoV-2 screening policy and associated misclassification bias, rather than by a causal impact of SARS-CoV-2. Evidence suggests that indirect impacts of the COVID-19 pandemic on pregnant women, such as those caused by delayed presentation and mental health problems, are far greater than the direct impacts of COVID-19 itself.2 , 3 It is therefore imperative that extra care is taken to design and interpret epidemiologic studies, avoiding biases that lead to spurious findings that may cause unwarranted distress.

The authors have based their selection of the exposed cohort on a positive SARS-CoV-2 test result at the time of birth admission. Defining the exposure in this way leads immediately to misclassification bias. Women who have an adverse pregnancy complication, such as antepartum stillbirth or preeclampsia, and who are therefore admitted, screened, and go on to have an induced birth will have any coincidental asymptomatic infection identified. Women who do not have a pregnancy complication and are consequently not admitted will not be screened, although they may have asymptomatic SARS-CoV-2 infection, and are therefore inappropriately excluded from the exposed cohort. By the time they are admitted to give birth, they are likely to have recovered from their infection and will be misclassified and placed in the unexposed cohort. The misclassification caused by the means of defining the exposed cohort will artificially elevate the apparent rate of death and complications in the exposed group and artificially reduce them in the unexposed group. Given that around two-thirds of COVID-19 infections in pregnant women are asymptomatic,4 this will be a substantial number of women, and this design flaw may entirely explain the findings.

Studies such as this can only be undertaken on a population basis, either in populations of pregnant women in whom regular, asymptomatic screening programs are conducted both at home and in hospital settings, or, in the absence of routine, regular population screening, by conducting a comparison between population antepartum stillbirth and preeclampsia rates comparing the time periods of when the virus is circulating and when it is not. Rigorous study designs must be employed to avoid causing additional unnecessary anxieties to pregnant women and their families.

Footnotes

On behalf of Mothers and Babies: Reducing Risk Through Audits and Confidential Enquiries Across the United Kingdom (MBRRACE-UK).

The authors report no conflict of interest.

This study did not receive any financial support.

References


Articles from American Journal of Obstetrics and Gynecology are provided here courtesy of Elsevier

RESOURCES